Nasdaq FDA - Search News

Amgen wins FDA nod for Lumakras

Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer

The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRASG12C inhibitor Lumakras as part of a combination regimen for adults with metastatic colorectal cancer (mCRC) whose tumors harbor an abnormal gene known as KRAS G12C.

Business Insider · 2d

Amgen announces FDA approval of Lumakras in combination with Vectibix

Amgen (AMGN) announced that the U.S. FDA has approved Lumakras in combination with Vectibix for the treatment of adult patients with KRAS

Reuters · 2d

US FDA approves Amgen's colorectal cancer therapy

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.

Nasdaq3d

FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition

Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second inflammatory bowel disease (IBD) condition, Crohn's disease (“CD”), in ...

2don MSN

AstraZeneca lymphoma therapy Calquence gets expanded approval in the U.S.

AstraZeneca (NASDAQ:AZN) announced Friday that the U.S. FDA approved its Bruton’s tyrosine kinase (BTK) inhibitor Calquence ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Amgen wins FDA nod for Lumakras

Trending now